Skip to Main Content

Paper Details

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
Eur Urol Oncol
7
2021
Author NameAffiliation
Michael J MorrisMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Martin E GleaveUniversity of British Columbia
Michael A CarducciSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fred SaadUniversity of Montreal Hospital Center (CHUM)
Howard I ScherMemorial Sloan Kettering Cancer Center, Weill Cornell Medical College
  • 1 - 5

Datasets

Release 1.2